Basis: Current FMP quote-based enterprise value / four-quarter operating income plus matched D&A. Source: stored company filings and market data; unavailable inputs remain N/A.
The EV/EBITDA ratio is N/A as of 2026-10-06T18:30:30.325Z.
Calculation as of: 2026-10-06T18:30:30.325Z.
Quote observation: 2026-10-06T18:30:09.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a5b8a39003d923715743cc0d1a2c59dcf36f227505f31b08d3d275f4059bcabd
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
EV/EBITDA RATIO
N/A
Attovia Therapeutics, Inc.
Market Cap
$765.90M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$759.58M
EV/EBITDA Ratio
18.27x
TTM Avg
16.06x
3Y Avg
17.33x
5Y Avg
27.55x
Market Cap
$775.12M
EV/EBITDA Ratio
N/A
TTM Avg
14.36x
3Y Avg
6.18x
5Y Avg
6.18x
Market Cap
$778.22M
EV/EBITDA Ratio
10.58x
TTM Avg
147.08x
3Y Avg
35.26x
5Y Avg
24.01x
Market Cap
$785.58M
EV/EBITDA Ratio
6.63x
TTM Avg
5.45x
3Y Avg
14.30x
5Y Avg
12.03x
Market Cap
$748.55M
EV/EBITDA Ratio
N/A
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$782.66M
EV/EBITDA Ratio
N/A
TTM Avg
800.36x
3Y Avg
800.36x
5Y Avg
800.36x
| NAME | MARKET CAP | EV/EBITDA RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Attovia Therapeutics, Inc. (ATTO) | $765.90M | N/A | N/A | N/A | N/A |
| Mesa Laboratories, Inc. (MLAB)vs › | $759.58M | 18.27x | 16.06x | 17.33x | 27.55x |
| Lexicon Pharmaceuticals, Inc. (LXRX)vs › | $775.12M | N/A | 14.36x | 6.18x | 6.18x |
| Varex Imaging Corporation (VREX)vs › | $778.22M | 10.58x | 147.08x | 35.26x | 24.01x |
| Sana Biotechnology, Inc. (SANA)vs › | $780.61M | N/A | N/A | N/A | N/A |
| AdaptHealth Corp. (AHCO)vs › | $785.58M | 6.63x | 5.45x | 14.30x | 12.03x |
| Apnimed, Inc. (APMD)vs › | $747.48M | N/A | N/A | N/A | N/A |
| Design Therapeutics, Inc. (DSGN)vs › | $748.55M | N/A | N/A | N/A | N/A |
| Geron Corporation (GERN)vs › | $782.66M | N/A | 800.36x | 800.36x | 800.36x |
| Gyre Therapeutics, Inc. (GYRE)vs › | $792.69M | N/A | 76.03x | 57.10x | 57.10x |
EV/EBITDA = Enterprise Value / EBITDA (TTM)
Enterprise value to EBITDA is a capital-structure-neutral valuation multiple, useful for comparing companies with different debt levels and tax rates.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
